ANN ARBOR, Mich., – January 7, 2025 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, is happy to announce the successful creation of a new transgenic, inspired by the Darwin’s bark spider (Caerostris darwini). This milestone represents a significant leap forward in the production of high-performance recombinant spider silk, setting the stage for a new benchmark for strength and toughness in engineered materials.

Darwin’s bark spider silk has been documented by some studies as the toughest biological material ever measured, over 10 times tougher than para-aramid fibers, the material used in bulletproof vests and other high-strength applications. Drawing upon these insights, Kraig Labs has successfully incorporated key genetic elements of this remarkable silk into its proprietary transgenic silkworms to create a scalable production system for this amazing material.

“This breakthrough underscores our commitment to pioneering cutting-edge materials inspired by nature’s most extraordinary designs,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “By leveraging the unique properties of Darwin’s bark spider silk, we are advancing the boundaries of what’s possible in biomaterial science and bringing us closer to commercial-scale production of ultra-high-performance fibers.”

The Company’s research team has integrated key genetic sequences derived from Darwin’s bark spider silk proteins into silkworms. This process combines the strength and elasticity of the Darwin’s bark spider silk with the efficiency of traditional silkworm silk production. This new transgenic marks the next in a series of transformative materials that Kraig Labs is developing for the textile, defense, medical, and industrial sectors.

“We recently reported that our molecular biology team was firing on all cylinders. Today’s announcement is a public disclosure of just one of the many breakthroughs that they recently achieved,” said COO of Kraig Labs, Jon Rice. “I expect that 2025 will be a year filled with many new and exciting developments from our labs while our production team delivers metric ton production of our existing hybrids.”

The Company sees this breakthrough as further reinforcement of its leading position in sustainable spider silk-based supermaterials. The Company’s transgenic silk technology not only opens the door for new commercial applications but also represents a significant step towards reducing environmental impacts in textile manufacturing.

For details about other recent advancements the Company has made, please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

As the year comes to a close and the holiday season wraps us in its warmth, we at Kraig Biocraft Laboratories want to take a moment to reflect on 2024—a year that will be remembered as a true turning point in our journey.

This year, we achieved what many thought impossible: the successful transition from innovation to production, unlocking the full potential of spider silk as a game-changing material. The introduction of our BAM-1 production hybrids was nothing short of transformative, propelling us into large-scale, sustainable spider silk manufacturing for the very first time.

In 2024, we produced over 1,200 pounds of recombinant spider silk cocoons—more material than we generated in all previous years combined. In fact, the last six months alone marked an incredible surge in production, with BAM-1 hybrids doubling cocoon size and silk yield. Each cycle brought stronger, healthier silkworms, bigger cocoons, and better results. As we enter this holiday season and reflect on the year behind us, I am filled with a sense of profound joy as we share these accomplishments together.

What we achieved this year is more than just numbers—it’s proof that perseverance, innovation, and teamwork can move mountains. It’s the culmination of years of dedication, and yet it feels like only the beginning. In 2025, we anticipate producing multiple tons of finished spider silk yarn, and firmly establishing Kraig Labs as the world leader in recombinant spider silk.

Beyond production, we’ve laid the groundwork for commercialization. We are entering 2025 ready to introduce our first offerings in luxury fashion and performance textiles, markets that are hungry for innovation and differentiation. The opportunity ahead is immense, and we couldn’t be more excited to see spider silk woven into products that inspire, protect, and perform.

On the science front, our molecular biology team delivered outstanding progress, creating advanced transgenic silkworm strains producing new fibers that the world has never seen before. We’ve had a series of significant breakthroughs in the lab under the leadership of our new head of molecular biology here at Kraig Labs. I look forward to introducing her to you, our shareholders and unveiling the new transgenics our team has created over these last few months. These developments are paving the way for even stronger, more versatile materials, ensuring that our leadership in spider silk technology will endure well into the future.

2024 was a year of breakthroughs, of milestones reached, and records set. We’re proud of what we’ve accomplished, but most importantly, we’re grateful—for our team, our partners, and for you, our loyal shareholders and supporters. Without your belief in our vision and your patience through every challenge we’ve overcome, none of this would be possible.

As we look to 2025, we do so with renewed energy and excitement for what lies ahead. We’ve proven that spider silk is no longer just a marvel of nature—it’s a reality we’re bringing to the world. Together, we are building something extraordinary.

From all of us at Kraig Labs, we wish you a joyful holiday season filled with love, laughter, and the company of those you hold dear. May the New Year bring you happiness, health, and success.

Thank you for standing with us. The best is yet to come.

Season’s Greetings, Happy New Year, Merry Christmas, and Happy Hanukkah to all our shareholders and the world.

Kim Thompson and the Kraig Labs’ Family

World’s First Commercially Viable Silkworms for Recombinant Spider Silk Production

ANN ARBOR, Mich., – December 16, 2024 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), the leading developer of spider silk-based fibers, reflects on a year of extraordinary progress following the introduction of its groundbreaking BAM-1 hybrids—the world’s first commercially viable silkworms recombinant spider silk production.

Since their debut earlier this year, the BAM-1 hybrids have proven to be a transformative innovation, driving significant advancements in silk production, cocoon size, yield, and silkworm robustness. These achievements validate the Company’s pioneering technology and its potential to revolutionize biomaterial manufacturing.

Over the past year, the BAM-1 hybrids have delivered remarkable results, including a doubling of cocoon size compared to traditional silkworms. This dramatic increase has directly translated to significantly higher silk yields, establishing new performance standards for productivity and efficiency in spider silk production.

In addition to improved yields, BAM-1 hybrids have demonstrated exceptional robustness and resilience. Their enhanced performance has been instrumental in advancing the scalability and consistency required for large-scale commercial operations, resulting in more than 1,200 pounds of recombinant spider silk cocoon production this year.

The BAM-1 hybrids are the world’s first silkworm for commercially viable recombinant spider silk production. By achieving reliable and repeatable yields at scale, Kraig Labs has set a new industry benchmark and opened the door to a wide range of applications, including technical textiles, defense, medical devices, and performance apparel.

“The introduction of the BAM-1 hybrid earlier this year marked a turning point for Kraig Biocraft Laboratories and for the future of spider silk production,” said Kim Thompson, CEO and Founder of Kraig Labs. “The extraordinary gains in cocoon size, silk yield, and silkworm resilience have validated our technology and enabled us to take significant steps toward industrial-scale production. This year has been about transforming promise into progress, and we are proud of what we have accomplished with BAM-1. Next year, we will expand on this success with production planning underway for multiple tons of spider silk production in 2025.”

The Company’s ongoing innovations and achievements in 2024 position Kraig Labs as a global leader in sustainable, high-performance spider silk production, unlocking new possibilities in biomaterials.

For more details about this breakthrough and other advancements the Company has made this year, please see the Company’s investor conference at www.kraiglabs.com/videos or through the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com